Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210315989METHODS TO PREPARE NASOPHARYNGEAL AND ORAL MATERIAL FOR ORAL INOCULATION OF COVID-19
US 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17223920 Applicant Steven Mark Hayden Inventor Steven Mark Hayden

The instant disclosure relates generally to oral inoculation and specifically to methods to prepare nasopharyngeal and oral material for oral inoculation of COVID-19. Severe acute respiratory syndrome coronavirus 2 (“SARS-CoV-2”) viral particles are collected from at least one of a nasopharyngeal specimen and an oral specimen each derived from a patient infected with SARS-CoV-2 or a SARS-CoV-2 variant. Mammalian cells (e.g., Vero-E6 and/or Vero-CCL81 cells) are infected with the SARS-CoV-2 viral particles to produce infected mammalian cells. The infected mammalian cells are cultured to produce a mammalian cell culture. SARS-CoV-2 viral particles are collected from the mammalian cell culture to produce isolated viral particles. The isolated viral particles are frozen to produce a frozen isolate. The frozen isolate is partitioned into a plurality of tablets each having a therapeutically effective amount of the SARS-CoV-2 viral particles. An enteric coating is applied to each tablet.

2.20210317454USE OF A TLR9 AGONIST IN METHODS FOR TREATING COVID-19
US 14.10.2021
Int.Class C12N 15/115
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
Appl.No 17226866 Applicant Idera Pharmaceuticals, Inc. Inventor Srinivas CHUNDURU

The present invention is directed to use of tilsotolimod in the treatment of coronavirus infection, for example, SARS-CoV2, and COVID-19.

3.WO/2021/207306RECOMBINANT BACTERIA FOR USE AS A VACCINE TO PREVENT COVID19 INFECTION
WO 14.10.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/026106 Applicant SYNLOGIC OPERATING COMPANY, INC. Inventor GAO, Jian-Rong
Modified microorganisms, pharmaceutical compositions thereof, and methods of preventing and treating the coronavirus disease 2019 (COVID-19) are disclosed.
4.WO/2021/205446PICKERING EMULSION-BASED VACCINES
WO 14.10.2021
Int.Class A61K 9/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
Appl.No PCT/IL2021/050390 Applicant THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) Inventor MECHREZ, Guy
A particle comprising a shell comprising an immunogenic nanoparticle bound to at least one epitope and in contact with the shell, is provided. An emulsion comprising a plurality of said particles is also provided, such as for vaccinating a subject in need thereof.
5.WO/2021/206587SARS-COV-2 DNA VACCINE BASED ON GENE THERAPY DNA VECTOR GDTT1.8NAS12
WO 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2021/000148 Applicant GENETIC DIAGNOSTICS AND THERAPY 21 LTD Inventor GAMOLSKI, Anton
The invention refers to genetic engineering and can be used in biotechnology, medicine as a DNA vaccine for human vaccination against SARS-CoV-2 virus. A DNA vaccine as a composition of gene therapy DNA vectors GDTT1.8NAS12-S, GDTT1.8NAS12-M, and GDTT1.8NAS12-N based on gene therapy DNA vector GDTT1.8NAS12 encoding immunogenic epitopes of S, M, and N proteins of SARS-CoV-2 virus was constructed. Each of the constructed gene therapy DNA vectors included in the DNA vaccine has the ability to efficiently penetrate human and animal cells and express the therapeutic S protein of SARS-CoV-2 cloned to it, therapeutic M protein of SARS-CoV-2 cloned to it and therapeutic N protein of SARS- CoV-2 cloned to it due to the limited size of GDTT1.8NAS12 vector part not exceeding 2600 bp. As part of each of the constructed gene therapy DNA vectors uses nucleotide sequences that are not antibiotic resistance genes or regulatory elements of viral genomes are used as the structural elements, which ensures its safe use for gene therapy and human vaccination.
6.WO/2021/207730VACCINES FOR CORONAVIRUS AND METHODS OF USING THE SAME
WO 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/026864 Applicant THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY Inventor KULP, Daniel, W.
Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a sequence that encodes a self-assembling polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence comprising a sequence that encodes an antigen from a virus from the family of Coronaviridae. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker.
7.102020002248Trans-Vakzine: Impfstoffe gegen virale Erkrankungen, basierend auf einer Kombination eines Virusgenoms mit einem deletierten essentiellen Gen mit einer genetisch modifizierten Zelllinie, die das Produkt des Gens in trans zur Verfügung stellt, sowie Mittel und Verfahren zu ihrer Herstellung sowie ihre Anwendungen, insbesondere zur Herstellung eines Impfstoffs gegen Coronaviren.
DE 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 102020002248 Applicant Flaig Rüdiger Marcus Inventor Antrag auf Nichtnennung

Die Erfindung betrifft einen Impfstoff gegen virale Erkrankungen, basierend auf einer Kombination eines Virusgenoms mit einem deletierten essentiellen Gen mit einer genetisch modifizierten Zelllinie, die das Produkt des Gens in trans zur Verfügung stellt, sowie Mittel und Verfahren zu seiner Herstellung sowie seine Anwendungen, insbesondere zur Herstellung eines Impfstoffs gegen Coronaviren.

8.WO/2021/206783VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE
WO 14.10.2021
Int.Class A61K 39/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
125Picornaviridae, e.g. calicivirus
13Poliovirus
Appl.No PCT/US2021/014253 Applicant XIE, Qiyi Inventor XIE, Qiyi
Provided herein is a poliomyelitis vaccine for use in preventing a person from an infection by a Coronaviridae virus. Also provided herein is a poliomyelitis vaccine for use in inducing a protective immune response in a person against a Coronaviridae virus.
9.WO/2021/203397ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF
WO 14.10.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2020/084097 Applicant TSB THERAPEUTICS (BEIJING) CO. LTD. Inventor ZHANG, Zheng
Provided herein are novel anti-SARS-COV-2 antibodies or antigen binding fragments thereof, pharmaceutical composition and kits comprising the same, and the uses thereof.
10.WO/2021/204969PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST AN INFECTION BY SARS-COV-2 (COVID-19)
WO 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2021/059232 Applicant EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET Inventor WALZ, Juliane
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of an infection by SARS-CoV-2 (COVID-19). The present invention furthermore relates to SARS-CoV2-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-SARS-CoV2 immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.